http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 07:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+Jul+15/26776721.html si-local-file:///var/storage/secattach/20260716/26776721.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+Jul+15/26776721.html Thu, 16 Jul 2026 07:31:00 -0400 ABUS O.01268577 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+Jul+15/26776721.html si-local-file:///var/storage/secattach/20260716/26776721.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+Jul+15/26776721.html Thu, 16 Jul 2026 07:31:00 -0400 ABUS O.01268577 http://www.streetinsider.com/Corporate+News/Arbutus+sues+Pfizer+and+BioNTech+over+LNP+patents+in+3+countries/26776707.html <p>Arbutus Biopharma Corporation (NASDAQ: ABUS) and its exclusive licensee, Genevant Sciences GmbH, a subsidiary of Roivant Sciences Ltd. (NASDAQ: ROIV), filed three international patent infringement lawsuits against Pfizer Inc. and BioNTech SE over the use of lipid nanoparticle (LNP) technology in their mRNA COVID-19 vaccines.</p><p>The cases were filed in the Federal Court of Canada and at the Unified Patent Court (UPC), with the UPC actions covering 19 European countries including Germany, France, Italy, and Spain. The suits seek permanent injunctions and monetary damages, including recovery of profits from alleged infringement of specific Canadian and European patents.</p><p>The international actions expand on http://www.streetinsider.com/Corporate+News/Arbutus+sues+Pfizer+and+BioNTech+over+LNP+patents+in+3+countries/26776707.html Thu, 16 Jul 2026 07:30:48 -0400 ABUS ROIV http://www.streetinsider.com/Corporate+News/Arbutus+sues+Pfizer+and+BioNTech+over+LNP+patents+in+3+countries/26776707.html <p>Arbutus Biopharma Corporation (NASDAQ: ABUS) and its exclusive licensee, Genevant Sciences GmbH, a subsidiary of Roivant Sciences Ltd. (NASDAQ: ROIV), filed three international patent infringement lawsuits against Pfizer Inc. and BioNTech SE over the use of lipid nanoparticle (LNP) technology in their mRNA COVID-19 vaccines.</p><p>The cases were filed in the Federal Court of Canada and at the Unified Patent Court (UPC), with the UPC actions covering 19 European countries including Germany, France, Italy, and Spain. The suits seek permanent injunctions and monetary damages, including recovery of profits from alleged infringement of specific Canadian and European patents.</p><p>The international actions expand on http://www.streetinsider.com/Corporate+News/Arbutus+sues+Pfizer+and+BioNTech+over+LNP+patents+in+3+countries/26776707.html Thu, 16 Jul 2026 07:30:48 -0400 ABUS ROIV http://www.streetinsider.com/Press+Releases/Arbutus+Initiates+International+Patent+Infringement+Enforcement+Actions+Against+Pfizer+and+BioNTech%2C+Receives+First+Payment+From+Moderna+Settlement+Agreement+and+Announces+Intent+to+Return+Capital+to+/26776680.html <p align="center"><strong>Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech </strong></p> <p align="center"><strong>Received approximately $178M from Moderna as Arbutus’ share of the noncontingent payment under the March 2026 Settlement Agreement resolving litigation over Moderna’s infringement of Arbutus’ LNP patents</strong></p> <p align="center"><strong>Anticipates receipt of a dividend from Genevant in Q3 2026</strong></p> <p align="center"><strong>Expects to return up to approximately $230M in capital to Arbutus shareholders</strong></p> <p align="justify">WARMINSTER, Pa., July 16, 2026 (GLOBE NEWSWIRE) http://www.streetinsider.com/Press+Releases/Arbutus+Initiates+International+Patent+Infringement+Enforcement+Actions+Against+Pfizer+and+BioNTech%2C+Receives+First+Payment+From+Moderna+Settlement+Agreement+and+Announces+Intent+to+Return+Capital+to+/26776680.html Thu, 16 Jul 2026 07:30:00 -0400 ABUS ABUS ROIV http://www.streetinsider.com/Press+Releases/Arbutus+Initiates+International+Patent+Infringement+Enforcement+Actions+Against+Pfizer+and+BioNTech%2C+Receives+First+Payment+From+Moderna+Settlement+Agreement+and+Announces+Intent+to+Return+Capital+to+/26776680.html <p align="center"><strong>Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech </strong></p> <p align="center"><strong>Received approximately $178M from Moderna as Arbutus’ share of the noncontingent payment under the March 2026 Settlement Agreement resolving litigation over Moderna’s infringement of Arbutus’ LNP patents</strong></p> <p align="center"><strong>Anticipates receipt of a dividend from Genevant in Q3 2026</strong></p> <p align="center"><strong>Expects to return up to approximately $230M in capital to Arbutus shareholders</strong></p> <p align="justify">WARMINSTER, Pa., July 16, 2026 (GLOBE NEWSWIRE) http://www.streetinsider.com/Press+Releases/Arbutus+Initiates+International+Patent+Infringement+Enforcement+Actions+Against+Pfizer+and+BioNTech%2C+Receives+First+Payment+From+Moderna+Settlement+Agreement+and+Announces+Intent+to+Return+Capital+to+/26776680.html Thu, 16 Jul 2026 07:30:00 -0400 ABUS ABUS ROIV http://www.streetinsider.com/Press+Releases/Arbutus+Initiates+International+Patent+Infringement+Enforcement+Actions+Against+Pfizer+and+BioNTech%2C+Receives+First+Payment+From+Moderna+Settlement+Agreement+and+Announces+Intent+to+Return+Capital+to+/26776680.html <p align="center"><strong>Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech </strong></p> <p align="center"><strong>Received approximately $178M from Moderna as Arbutus’ share of the noncontingent payment under the March 2026 Settlement Agreement resolving litigation over Moderna’s infringement of Arbutus’ LNP patents</strong></p> <p align="center"><strong>Anticipates receipt of a dividend from Genevant in Q3 2026</strong></p> <p align="center"><strong>Expects to return up to approximately $230M in capital to Arbutus shareholders</strong></p> <p align="justify">WARMINSTER, Pa., July 16, 2026 (GLOBE NEWSWIRE) http://www.streetinsider.com/Press+Releases/Arbutus+Initiates+International+Patent+Infringement+Enforcement+Actions+Against+Pfizer+and+BioNTech%2C+Receives+First+Payment+From+Moderna+Settlement+Agreement+and+Announces+Intent+to+Return+Capital+to+/26776680.html Thu, 16 Jul 2026 07:30:00 -0400 ABUS ABUS ROIV http://www.streetinsider.com/Globe+Newswire/Arbutus+Initiates+International+Patent+Infringement+Enforcement+Actions+Against+Pfizer+and+BioNTech%2C+Receives+First+Payment+From+Moderna+Settlement+Agreement+and+Announces+Intent+to+Return+Capital+to+/26776680.html <p align="center"><strong>Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech </strong></p> <p align="center"><strong>Received approximately $178M from Moderna as Arbutus’ share of the noncontingent payment under the March 2026 Settlement Agreement resolving litigation over Moderna’s infringement of Arbutus’ LNP patents</strong></p> <p align="center"><strong>Anticipates receipt of a dividend from Genevant in Q3 2026</strong></p> <p align="center"><strong>Expects to return up to approximately $230M in capital to Arbutus shareholders</strong></p> <p align="justify">WARMINSTER, Pa., July 16, 2026 (GLOBE NEWSWIRE) http://www.streetinsider.com/Globe+Newswire/Arbutus+Initiates+International+Patent+Infringement+Enforcement+Actions+Against+Pfizer+and+BioNTech%2C+Receives+First+Payment+From+Moderna+Settlement+Agreement+and+Announces+Intent+to+Return+Capital+to+/26776680.html Thu, 16 Jul 2026 07:30:00 -0400 ABUS ABUS ROIV http://www.streetinsider.com/Globe+Newswire/Arbutus+Initiates+International+Patent+Infringement+Enforcement+Actions+Against+Pfizer+and+BioNTech%2C+Receives+First+Payment+From+Moderna+Settlement+Agreement+and+Announces+Intent+to+Return+Capital+to+/26776680.html <p align="center"><strong>Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech </strong></p> <p align="center"><strong>Received approximately $178M from Moderna as Arbutus’ share of the noncontingent payment under the March 2026 Settlement Agreement resolving litigation over Moderna’s infringement of Arbutus’ LNP patents</strong></p> <p align="center"><strong>Anticipates receipt of a dividend from Genevant in Q3 2026</strong></p> <p align="center"><strong>Expects to return up to approximately $230M in capital to Arbutus shareholders</strong></p> <p align="justify">WARMINSTER, Pa., July 16, 2026 (GLOBE NEWSWIRE) http://www.streetinsider.com/Globe+Newswire/Arbutus+Initiates+International+Patent+Infringement+Enforcement+Actions+Against+Pfizer+and+BioNTech%2C+Receives+First+Payment+From+Moderna+Settlement+Agreement+and+Announces+Intent+to+Return+Capital+to+/26776680.html Thu, 16 Jul 2026 07:30:00 -0400 ABUS ABUS ROIV http://www.streetinsider.com/Globe+Newswire/Arbutus+Initiates+International+Patent+Infringement+Enforcement+Actions+Against+Pfizer+and+BioNTech%2C+Receives+First+Payment+From+Moderna+Settlement+Agreement+and+Announces+Intent+to+Return+Capital+to+/26776680.html <p align="center"><strong>Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech </strong></p> <p align="center"><strong>Received approximately $178M from Moderna as Arbutus’ share of the noncontingent payment under the March 2026 Settlement Agreement resolving litigation over Moderna’s infringement of Arbutus’ LNP patents</strong></p> <p align="center"><strong>Anticipates receipt of a dividend from Genevant in Q3 2026</strong></p> <p align="center"><strong>Expects to return up to approximately $230M in capital to Arbutus shareholders</strong></p> <p align="justify">WARMINSTER, Pa., July 16, 2026 (GLOBE NEWSWIRE) http://www.streetinsider.com/Globe+Newswire/Arbutus+Initiates+International+Patent+Infringement+Enforcement+Actions+Against+Pfizer+and+BioNTech%2C+Receives+First+Payment+From+Moderna+Settlement+Agreement+and+Announces+Intent+to+Return+Capital+to+/26776680.html Thu, 16 Jul 2026 07:30:00 -0400 ABUS ABUS ROIV http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arbutus+Biopharma+Corp++++For%3A+Jun+08++Filed+by%3A+Sawhney+Roger/26629852.html si-local-file:///var/storage/secattach/20260610/26629852.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arbutus+Biopharma+Corp++++For%3A+Jun+08++Filed+by%3A+Sawhney+Roger/26629852.html Wed, 10 Jun 2026 16:06:00 -0400 ABUS O.01268577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arbutus+Biopharma+Corp++++For%3A+Jun+08++Filed+by%3A+Sawhney+Roger/26629852.html si-local-file:///var/storage/secattach/20260610/26629852.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arbutus+Biopharma+Corp++++For%3A+Jun+08++Filed+by%3A+Sawhney+Roger/26629852.html Wed, 10 Jun 2026 16:06:00 -0400 ABUS O.01268577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arbutus+Biopharma+Corp++++For%3A+Jun+08++Filed+by%3A+Beardsley+Robert+A/26629840.html si-local-file:///var/storage/secattach/20260610/26629840.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arbutus+Biopharma+Corp++++For%3A+Jun+08++Filed+by%3A+Beardsley+Robert+A/26629840.html Wed, 10 Jun 2026 16:05:00 -0400 ABUS O.01268577 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arbutus+Biopharma+Corp++++For%3A+Jun+08++Filed+by%3A+Beardsley+Robert+A/26629840.html si-local-file:///var/storage/secattach/20260610/26629840.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arbutus+Biopharma+Corp++++For%3A+Jun+08++Filed+by%3A+Beardsley+Robert+A/26629840.html Wed, 10 Jun 2026 16:05:00 -0400 ABUS O.01268577 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Arbutus+Biopharma+Corp+++++++++++++++/26611028.html si-local-file:///var/storage/secattach/20260605/26611028.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Arbutus+Biopharma+Corp+++++++++++++++/26611028.html Fri, 05 Jun 2026 16:06:00 -0400 ABUS O.01268577 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Arbutus+Biopharma+Corp+++++++++++++++/26611028.html si-local-file:///var/storage/secattach/20260605/26611028.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Arbutus+Biopharma+Corp+++++++++++++++/26611028.html Fri, 05 Jun 2026 16:06:00 -0400 ABUS O.01268577 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+May+26/26557633.html si-local-file:///var/storage/secattach/20260527/26557633.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+May+26/26557633.html Wed, 27 May 2026 16:02:00 -0400 ABUS O.01268577 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+May+26/26557633.html si-local-file:///var/storage/secattach/20260527/26557633.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+May+26/26557633.html Wed, 27 May 2026 16:02:00 -0400 ABUS O.01268577 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Arbutus+Biopharma+Corp+++++++++++++++++Filed+by%3A+Two+Seas+Capital+LP/26508052.html si-local-file:///var/storage/secattach/20260515/26508052.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Arbutus+Biopharma+Corp+++++++++++++++++Filed+by%3A+Two+Seas+Capital+LP/26508052.html Fri, 15 May 2026 17:34:00 -0400 ABUS O.01268577 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Arbutus+Biopharma+Corp+++++++++++++++++Filed+by%3A+Two+Seas+Capital+LP/26508052.html si-local-file:///var/storage/secattach/20260515/26508052.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Arbutus+Biopharma+Corp+++++++++++++++++Filed+by%3A+Two+Seas+Capital+LP/26508052.html Fri, 15 May 2026 17:34:00 -0400 ABUS O.01268577 http://www.streetinsider.com/Earnings/Arbutus+Biopharma+%28ABUS%29+Tops+Q1+EPS+by+91c/26481863.html <p>Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of $0.87, $0.91 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $179.23 million versus the consensus estimate of $400 thousand.</p><p>For earnings history and earnings-related data on Arbutus Biopharma (ABUS) <a href="http://www.streetinsider.com/ec_earnings.php?q=ABUS">click here</a>.</p> http://www.streetinsider.com/Earnings/Arbutus+Biopharma+%28ABUS%29+Tops+Q1+EPS+by+91c/26481863.html Wed, 13 May 2026 07:47:39 -0400 ABUS http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Arbutus+Biopharma+Corp++++For%3A+Mar+31/26481773.html si-local-file:///var/storage/secattach/20260513/26481773.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Arbutus+Biopharma+Corp++++For%3A+Mar+31/26481773.html Wed, 13 May 2026 07:32:00 -0400 ABUS O.01268577 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Arbutus+Biopharma+Corp++++For%3A+Mar+31/26481773.html si-local-file:///var/storage/secattach/20260513/26481773.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Arbutus+Biopharma+Corp++++For%3A+Mar+31/26481773.html Wed, 13 May 2026 07:32:00 -0400 ABUS O.01268577 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+May+13/26481766.html si-local-file:///var/storage/secattach/20260513/26481766.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+May+13/26481766.html Wed, 13 May 2026 07:31:00 -0400 ABUS O.01268577 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+May+13/26481766.html si-local-file:///var/storage/secattach/20260513/26481766.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+May+13/26481766.html Wed, 13 May 2026 07:31:00 -0400 ABUS O.01268577